133 related articles for article (PubMed ID: 21690244)
1. HER2 testing in the UK: recommendations for breast and gastric in-situ hybridisation methods.
Bartlett JM; Starczynski J; Atkey N; Kay E; O'Grady A; Gandy M; Ibrahim M; Jasani B; Ellis IO; Pinder SE; Walker RA
J Clin Pathol; 2011 Aug; 64(8):649-53. PubMed ID: 21690244
[TBL] [Abstract][Full Text] [Related]
2. HER2 testing in the UK: further update to recommendations.
Walker RA; Bartlett JM; Dowsett M; Ellis IO; Hanby AM; Jasani B; Miller K; Pinder SE
J Clin Pathol; 2008 Jul; 61(7):818-24. PubMed ID: 18381380
[TBL] [Abstract][Full Text] [Related]
3. Simultaneous analysis of HER2 gene and protein on a single slide facilitates HER2 testing of breast and gastric carcinomas.
Hirschmann A; Lamb TA; Marchal G; Padilla M; Diebold J
Am J Clin Pathol; 2012 Dec; 138(6):837-44. PubMed ID: 23161718
[TBL] [Abstract][Full Text] [Related]
4. A quality assurance exercise to evaluate the accuracy and reproducibility of chromogenic in situ hybridisation for HER2 analysis in breast cancer.
Di Palma S; Collins N; Bilous M; Sapino A; Mottolese M; Kapranos N; Schmitt F; Isola J
J Clin Pathol; 2008 Jun; 61(6):757-60. PubMed ID: 18326010
[TBL] [Abstract][Full Text] [Related]
5. Establishment of the Australian in situ hybridization program for the assessment of HER2 amplification in breast cancer: a model for the introduction of new biomarkers into clinical practice.
Farshid G; Armes JE; Bell R; Cummings M; Fox S; Francis G; Haswell M; Morey A; McCue G; Raymond W; Robbins P; Bilous M
Diagn Mol Pathol; 2010 Dec; 19(4):187-93. PubMed ID: 21052003
[TBL] [Abstract][Full Text] [Related]
6. Updated UK Recommendations for HER2 assessment in breast cancer.
Rakha EA; Pinder SE; Bartlett JM; Ibrahim M; Starczynski J; Carder PJ; Provenzano E; Hanby A; Hales S; Lee AH; Ellis IO;
J Clin Pathol; 2015 Feb; 68(2):93-9. PubMed ID: 25488926
[TBL] [Abstract][Full Text] [Related]
7. HER2 gene amplification in breast cancer: a rogues' gallery of challenging diagnostic cases: UKNEQAS interpretation guidelines and research recommendations.
Starczynski J; Atkey N; Connelly Y; O'Grady T; Campbell FM; di Palma S; Wencyk P; Jasani B; Gandy M; Bartlett JM;
Am J Clin Pathol; 2012 Apr; 137(4):595-605. PubMed ID: 22431536
[TBL] [Abstract][Full Text] [Related]
8. Current perspectives on HER2 testing: a review of national testing guidelines.
Bilous M; Dowsett M; Hanna W; Isola J; Lebeau A; Moreno A; Penault-Llorca F; Rüschoff J; Tomasic G; van de Vijver M
Mod Pathol; 2003 Feb; 16(2):173-82. PubMed ID: 12591971
[TBL] [Abstract][Full Text] [Related]
9. Bright-field in situ hybridization for HER2 gene amplification in breast cancer using tissue microarrays: correlation between chromogenic (CISH) and automated silver-enhanced (SISH) methods with patient outcome.
Francis GD; Jones MA; Beadle GF; Stein SR
Diagn Mol Pathol; 2009 Jun; 18(2):88-95. PubMed ID: 19430296
[TBL] [Abstract][Full Text] [Related]
10. HER2 testing recommendations in the UK: dual- or single-colour in-situ hybridisation?
Moelans CB; van Diest PJ
J Clin Pathol; 2012 Apr; 65(4):379. PubMed ID: 22031588
[No Abstract] [Full Text] [Related]
11. HER2 assessment by silver in situ hybridization: where are we now?
Sanguedolce F; Bufo P
Expert Rev Mol Diagn; 2015 Mar; 15(3):385-98. PubMed ID: 25578771
[TBL] [Abstract][Full Text] [Related]
12. External quality assurance of HER2 FISH and ISH testing: three years of the UK national external quality assurance scheme.
Bartlett JM; Ibrahim M; Jasani B; Morgan JM; Ellis I; Kay E; Connolly Y; Campbell F; O'Grady A; Barnett S; Miller K
Am J Clin Pathol; 2009 Jan; 131(1):106-11. PubMed ID: 19095573
[TBL] [Abstract][Full Text] [Related]
13. Quantitative analysis of diagnostic guidelines for HER2-status assessment.
Stenzinger A; von Winterfeld M; Aulmann S; Warth A; Weichert W; Denkert C; Rüschoff J; Dietel M; Klauschen F
J Mol Diagn; 2012; 14(3):199-205. PubMed ID: 22500949
[TBL] [Abstract][Full Text] [Related]
14. Breast carcinomas with borderline (2+) HER2 immunohistochemistry: percentage of cells with complete membrane staining for HER2 and the frequency of HER2 amplification.
Lee AH; Key HP; Bell JA; Hodi Z; Ellis IO
J Clin Pathol; 2011 Jun; 64(6):490-2. PubMed ID: 21415056
[TBL] [Abstract][Full Text] [Related]
15. Current technologies for HER2 testing in breast cancer.
Moelans CB; de Weger RA; Van der Wall E; van Diest PJ
Crit Rev Oncol Hematol; 2011 Dec; 80(3):380-92. PubMed ID: 21273092
[TBL] [Abstract][Full Text] [Related]
16. Classification of HER2/neu status in gastric cancer using a breast-cancer derived proteome classifier.
Balluff B; Elsner M; Kowarsch A; Rauser S; Meding S; Schuhmacher C; Feith M; Herrmann K; Röcken C; Schmid RM; Höfler H; Walch A; Ebert MP
J Proteome Res; 2010 Dec; 9(12):6317-22. PubMed ID: 21058730
[TBL] [Abstract][Full Text] [Related]
17. Performance of chromogenic in situ hybridization on testing HER2 Status in breast carcinomas with chromosome 17 polysomy and equivocal (2+) herceptest results: a study of two institutions using the conventional and new ASCO/CAP scoring criteria.
Gong Y; Sweet W; Duh YJ; Greenfield L; Tarco E; Trivedi S; Symmans WF; Isola J; Sneige N
Am J Clin Pathol; 2009 Aug; 132(2):228-36. PubMed ID: 19605817
[TBL] [Abstract][Full Text] [Related]
18. Human epidermal growth factor receptor 2 testing in gastric carcinoma: issues related to heterogeneity in biopsies and resections.
Lee S; de Boer WB; Fermoyle S; Platten M; Kumarasinghe MP
Histopathology; 2011 Nov; 59(5):832-40. PubMed ID: 22092394
[TBL] [Abstract][Full Text] [Related]
19. Chromogenic in situ hybridisation testing for HER2 gene amplification in breast cancer produces highly reproducible results concordant with fluorescence in situ hybridisation and immunohistochemistry.
Bilous M; Morey A; Armes J; Cummings M; Francis G
Pathology; 2006 Apr; 38(2):120-4. PubMed ID: 16581651
[TBL] [Abstract][Full Text] [Related]
20. Guidelines for HER2 testing in breast cancer: a national consensus of the Spanish Society of Pathology (SEAP) and the Spanish Society of Medical Oncology (SEOM).
Albanell J; Andreu X; Calasanz MJ; Concha A; Corominas JM; García-Caballero T; López JA; López-Ríos F; Ramón y Cajal S; Vera-Sempere FJ; Colomer R; Martín M; Alba E; González-Martín A; Llombart A; Lluch A; Palacios J
Clin Transl Oncol; 2009 Jun; 11(6):363-75. PubMed ID: 19531451
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
